Packaging and component compatibility studies evaluate the interactions between pharmaceutical products and their direct-contact materials, including container closure systems, elastomeric seals, fluid-path tubing, drug-delivery devices (plastics, rubber, glass, coatings, etc.), and single-use storage bags. The scope encompasses the assessment of extractables and leachable, sorption, permeation, and catalyzed degradation risks. Such studies constitute a mandatory research component for pharmaceutical registration submissions before regulatory authorities worldwide.
Far from being an isolated physicochemical exercise, compatibility verification represents a continuous risk-control system that spans the entire product lifecycle—from R&D through registration and post-approval change management. It bears direct implications for product safety, efficacy, and quality controllability. The appropriate timing for conducting compatibility studies varies across development phases, with correspondingly distinct submission value and risk consequences.
1. Early-Stage R&D (Formulation and Packaging Screening; IND / Pre-clinical Phase)
Implementation
Appropriate packaging materials shall be screened at the early R&D stage to preclude large-scale rework of formulations and packaging systems arising from incompatibility identified only during pilot-scale production or registration submission.
Upon clarification of the physicochemical properties of the active pharmaceutical ingredient (API) and excipients at the onset of formulation and process development, packaging screening shall be initiated in parallel.
Pre-screening studies: Preliminary compatibility experiments shall be performed for candidate materials (e.g., glass, COC/COP, CPE), elastomeric seals, and drug-delivery assemblies. Key observations include appearance changes, pH drift, and sorption, so as to eliminate demonstrably incompatible materials.
Risk assessment: Pre-screening may leverage technical documentation provided by material suppliers. Full extractables characterisation is not required at this stage; however, high-risk materials (e.g., certain rubber stopper formulations) shall be excluded based on toxicological data.
Core Significance
1. Mitigate disruptive risks: Identify major compatibility issues—such as API sorption, drug degradation, discoloration, or visible particulate matter—at an early stage, thereby preventing misdirection in R&D strategy.
2. Lock in the packaging system: Confirm a suitable container closure system as early as possible. Avoid additional bridging studies triggered by packaging substitution during clinical trials, substantially reducing R&D cycle time and cost.
3. Submission perspective: Insufficient justification for packaging selection at the IND stage may necessitate partial repetition of non-clinical studies if packaging modifications are implemented after clinical trial authorization has been granted.
Key Regulatory Reference
ICH Q8 (Pharmaceutical Development) embodies the Quality by Design (QbD) concept, requiring assessment of container–product interactions at early development stages.
2.4 Container Closure System The choice and rationale for selection of the container closure system for the commercial product (described in 3.2.P.7) should be discussed. Consideration should be given to the intended use of the drug product and the suitability of the container closure system for storage and transportation (shipping), including the storage and shipping container for bulk drug product, where appropriate.
The choice of materials for primary packaging should be justified. The discussion should describe studies performed to demonstrate the integrity of the container and closure. A possible interaction between product and container or label should be considered.
The choice of primary packaging materials should consider, e.g., choice of materials, protection from moisture and light, compatibility of the materials of construction with the dosage form (including sorption to container and leaching), and safety of materials of construction. Justification for secondary packaging materials should be included, when relevant.
If a dosing device is used (e.g., dropper pipette, pen injection device, dry powder inhaler), it is important to demonstrate that a reproducible and accurate dose of the product is delivered under testing conditions which, as far as possible, simulate the use of the product.
Chinese Pharmacopoeia 2025, newly added General Chapter 9621 General Guiding Principles for Pharmaceutical Packaging Materials, introduces for the first time the compatibility concept for pharmaceutical packaging systems, mandating suitability evaluation across four dimensions: protection, compatibility, safety, and functionality.
On the basis of confirming that pharmaceutical packaging materials meet their intended purpose, critical quality attributes (CQAs) shall be defined through necessary research and assessment in accordance with full-lifecycle risk-management requirements. In-house specifications shall be established with reference to relevant pharmacopoeial guidelines for packaging materials, and quality control shall be implemented accordingly. Quality control generally includes, but is not limited to:
Physical properties: Key physical characteristics (e.g., density, linear coefficient of thermal expansion of glass), protective performance (e.g., container closure integrity, barrier properties), and functional performance (e.g., puncture force, plunger gliding performance of pre-filled syringes)—physical parameters that may affect pharmaceutical quality and usability.
Chemical properties: Chemical quality attributes examined via identification (e.g., infrared spectroscopy, ash content of rubber seals), extractables testing (e.g., oxidisable substances, UV absorbance), and residue determination (e.g., residual solvents, residual monomers).
Visible particles and sub-visible particulate matter.
Sterility, microbial limits, and bacterial endotoxins.
Manufacturers and end-users of pharmaceutical packaging materials shall apply full-lifecycle quality management and risk-management principles. Statistical tools or relevant standards may be adopted to establish appropriate test types and acceptance criteria, satisfying quality-control requirements while ensuring testing practicality.
2. Clinical Research Phase (Phase I / II / III Clinical Trials)
Implementation
Simulate commercial-scale production: Packaging systems intended for commercial products—including material grades, part numbers, and suppliers—shall in principle be adopted for clinical trial samples. Preliminary extractables studies may be initiated for terminally sterilised products, high-risk biological products, and injectable formulations.
Core Significance
1. Ensure that packaging and production-contact components for clinical samples are substantially consistent with the commercial configuration, thereby enabling extrapolation of clinical trial data to marketed products.
2. Identify long-term latent risks: Detect long-term storage-related interactions between packaging and drug product (e.g., silicone oil shedding, increased particulate levels) through extended-duration validation.
3. Preliminary compatibility data serve as supporting documentation; the rationale for packaging selection shall be summarised in clinical submission dossiers.
Common deficiency risk: Discrepancies between clinical-trial packaging and the proposed commercial packaging will trigger requests for comparative data or supplementary studies by CDE.
Key Regulatory Reference
ICH Q5C (Stability Testing of Biotechnological/Biological Products) requires assessment of container–closure compatibility and seal integrity during clinical development for biological products.
6.5. Container/Closure Changes in the quality of the product may occur due to the interactions between the formulated biotechnological/biological product and container/closure. Where the lack of interactions cannot be excluded in liquid products (other than sealed ampoules), stability studies should include samples maintained in the inverted or horizontal position (i.e., in contact with the closure), as well as in the upright position, to determine the effects of the closure on product quality. Data should be supplied for all different container/closure combinations that will be marketed.
In addition to the standard data necessary for a conventional single-use vial, the applicant should demonstrate that the closure used with a multiple-dose vial is capable of withstanding the conditions of repeated insertions and withdrawals so that the product retains its full potency, purity, and quality for the maximum period.
Technical Guiding Principles for Compatibility Studies between Chemical Injectable Products and Pharmaceutical Glass Packaging Containers (Trial) specifies requirements for glass containers (e.g., glass delamination, heavy-metal migration) in pre-clinical and clinical phases for injectables.
Introduction This guiding principle elaborates compatibility studies between injectable products and glass packaging containers. It aims to guide R&D and manufacturing enterprises to conduct systematic and standardised compatibility studies, select appropriate pharmaceutical glass containers during drug development, confirm the suitability of glass packaging systems for chemical injectables throughout development, and ultimately adopt well-matched glass containers, so as to avoid safety risks potentially arising from pharmaceutical packaging.
3. Registration Submission Phase (NDA / ANDA)
Implementation
This represents the formal, statutorily mandated core phase for compatibility studies. Full-scale studies shall be conducted using finalised formulations, commercial specifications, and production-grade packaging materials. The scope encompasses extractables testing, leachables testing, interaction characterisation (compatibility profiling, related-substances testing, sorption, pH, particulate matter, etc.), and toxicological safety assessment (PDE / SCT calculation). A formal Compatibility Study Report shall be compiled.
Core Significance
1. Mandatory compliance threshold: Compatibility reports constitute essential documentation for high-risk dosage forms, including injectables, ophthalmic products, inhaled products, and biological products. Missing reports or flawed study designs will directly result in dossier deficiency notices or suspended review.
2. Support shelf-life determination: Compatibility data shall correlate with long-term stability results, providing evidence that packaging-driven product degradation remains controlled throughout the shelf life, and forming a key evidentiary basis for establishing storage conditions and expiry dates.
3. Impurity traceability for regulatory inquiries: When unknown related substances are detected in stability batches, compatibility studies differentiate impurity origins—API degradation, excipient interactions, or packaging-leachable-induced degradation. Failure to provide a rational interpretation of impurities is a frequent cause of non-acceptance during review.
4. Safety-justification basis: Qualitative and quantitative characterization of leachable, combined with toxicological assessment, demonstrates that migrated substances are safely controlled, thereby mitigating patient safety risks from extraneous impurities—a top regulatory concern.
Key Regulatory Reference
ICH Q3D (Elemental Impurities) defines Permitted Daily Exposure (PDE) values and assessment pathways for heavy metals and other elemental impurities potentially migrating from packaging materials.
Introduction Elemental impurities in drug products may arise from several sources; they may be residual catalysts that were added intentionally in synthesis or may be present as impurities (e.g., through interactions with processing equipment or container/closure systems or by being present in components of the drug product). Because elemental impurities do not provide any therapeutic benefit to the patient, their levels in the drug product should be controlled within acceptable limits. There are three parts of this guideline: the evaluation of the toxicity data for potential elemental impurities; the establishment of a Permitted Daily Exposure (PDE) for each element of toxicological concern; and application of a risk-based approach to control elemental impurities in drug products. An applicant is not expected to tighten the limits based on process capability, provided that the elemental impurities in drug products do not exceed the PDEs. The PDEs established in this guideline are considered to be protective of public health for all patient populations. In some cases, lower levels of elemental impurities may be warranted when levels below toxicity thresholds have been shown to have an impact on other quality attributes of the drug product (e.g., element catalysed degradation of drug substances). In addition, for elements with high PDEs, other limits may have to be considered from a pharmaceutical quality perspective and other guidelines should be consulted (e.g., ICH Q3A).
This guideline presents a process to assess and control elemental impurities in the drug product using the principles of risk management as described in ICH Q9. This process provides a platform for developing a risk-based control strategy to limit elemental impurities in the drug product.
Scope The guideline applies to new finished drug products (as defined in ICH Q6A and Q6B) and new drug products containing existing drug substances. The drug products containing purified proteins and polypeptides (including proteins and polypeptides produced from recombinant or non-recombinant origins), their derivatives, and products of which they are components (e.g., conjugates) are within the scope of this guideline, as are drug products containing synthetically produced polypeptides, polynucleotides, and oligosaccharides.
USP <1663> and <1664>: Core United States Pharmacopoeia general chapters governing extractables and leachables, detailing analytical method validation, toxicological threshold establishment, and safety-evaluation workflows.
Technical Guiding Principles for Compatibility Studies between Chemical Injectable Products and Plastic Packaging Materials (Trial): For plastic packaging, specifies high-priority additives (e.g., antioxidants, plasticisers) and regulatory specifications for leachables studies.
4. Review and Inspection Phase
Implementation
Technical review: Regulatory reviewers primarily assess the scientific rationale of compatibility study protocols, the completeness of raw data, the representativeness of test samples, and the accuracy of toxicological limit calculations.
Core Significance
1. Avoid deficiency requests and application rejection: Where test samples fail to represent commercial packaging (e.g., laboratory-scale data substituted for production-scale data), leachables safety assessment is absent, or spectral interpretation is inadequate, formal deficiency letters will be issued.
2. Data integrity: Incomplete source records or improperly designed test conditions (e.g., inappropriate extraction solvent selection) constitute major deficiencies in pivotal studies, directly impacting review outcomes.
Key Regulatory Reference
Measures for Drug Registration stipulates statutory requirements for on-site inspection of drug registration submissions, emphasising consistency between submitted dossiers and original records.
PQRI (Product Quality Research Institute) recommendations: An internationally recognised best-practice framework for packaging compatibility studies, frequently adopted by CDE and FDA as benchmarks for evaluating the scientific validity of study protocols.
5. Post-Approval Full-Lifecycle Phase (Post-Marketing Changes)
Implementation
Comparative compatibility studies of appropriate scope shall be initiated upon changes including packaging-material supplier replacement, material part-number modification, rubber stopper/plunger grade substitution, primary-packaging specification adjustment, or formulation/process modifications (e.g., pH or solvent variations). Study scope shall be determined in accordance with change-management guidelines.
Core Significance
1. Change compliance: Moderate or major variations require submission of comparative compatibility data. Supplementary applications will be rejected without supporting test data, potentially resulting in product suspension.
2. Common pitfall: Many enterprises replace packaging for cost reduction after commercial launch without sufficient assessment, which may lead to non-compliance during market surveillance (e.g., excessive sub-visible particulate matter).
Key Regulatory Reference
Measures for the Administration of Drug Registration Changes defines scenarios in which packaging modifications qualify as moderate or major changes, together with corresponding submission-dossier requirements.
ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management) provides an internationally harmonized framework for the management, risk assessment, and submission strategies for post-approval container closure system changes.
Conclusion
Compatibility studies traverse the complete pharmaceutical submission lifecycle: pre-clinical screening → clinical research → registration submission → technical review and inspection → post-marketing changes.
From a submission perspective, compatibility verification is not merely a set of physicochemical tests. It constitutes an integrated evidence system supporting packaging selection, extrapolation of clinical data, expiry-date establishment, impurity-profile elucidation, and variation filings, and exerts direct influence on project timelines, review outcomes, and sustained post-marketing compliance.
Deferring compatibility work until late-stage submission frequently results in packaging incompatibility, the need for repeat testing, and extensive regulatory deficiency requests.
Strategic recommendation: Adopt the rational sequence—early-stage screening to lock in packaging systems, full formal compatibility studies at the registration stage, and continuous evaluation for post-marketing changes.
